Therapeutic approaches to slowing the progression of diabetic nephropathy -is less best?

Drugs in Context

Volumn , Issue , 2013, Pages

  Vivian, Eva ^a   Mannebach, Chelsea ^b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b IDAHO STATE UNIVERSITY   (United States)

Author keywords

Angiotensin II receptor blockers; Angiotensin converting enzyme inhibitors; Calcium channel blockers; Combination therapy; Diabetes mellitus; Diabetic nephropathy; Direct renin inhibitors; Microvascular complications

Indexed keywords

ALISKIREN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CANDESARTAN; CAPTOPRIL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IMIDAPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; NIFEDIPINE; NITRENDIPINE; PLACEBO; RAMIPRIL; RENIN INHIBITOR; TELMISARTAN; VALSARTAN;

ACUTE KIDNEY FAILURE; ALBUMINURIA; BLOOD PRESSURE REGULATION; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HUMAN; HYPERKALEMIA; HYPERTENSION; MACROALBUMINURIA; MICROALBUMINURIA; MONOTHERAPY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PROTEIN INTAKE; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; URINALYSIS;

EID: 84876477916     PISSN: 17451981     EISSN: 17404398     Source Type: Journal    
DOI: 10.7573/dic.212249     Document Type: Review

References (69)

1. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005;28:164-76. (Pubitemid 40095801)
2. Collins AJ, Foley RN, Chavers B et al. United States Renal Data System 2012 Annual Data Report. Am J Kidney Dis 2012;59(1 Suppl 1):A7,e1-420.
3. Garg JP, Bakris GL. Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med 2002;7:35-43. (Pubitemid 34654072)
4. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 2004;110:32-5. (Pubitemid 38880131)
5. Klag MJ, Whelton PK, Randall BL et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996;334: 13-8. (Pubitemid 26012498)
6. U.S. Department of Health and Human Services. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. 2003. Available at: http://www.nhlbi.nih.gov/guidelines/ hypertension/jncintro.htm. [Last accessed: 6 April 2012].
7. Wang SL, Head J, Stevens L, Fuller JH. Excess mortality and its relation to hypertension and proteinuria in diabetic patients. The World Health Organization multinational study of vascular disease in diabetes. Diabetes Care 1996;19: 305-12. (Pubitemid 26115451)
8. Larkins RG, Dunlop ME. The link between hyperglycaemia and diabetic nephropathy. Diabetologia 1992;35:499-504.
9. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011.
10. American Diabetes Association. Standards of medical care in diabetes -2013. Diabetes Care 2013;36(Suppl 1):S11-66.
11. ONTARGET Investigators: Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59. (Pubitemid 351522739)
12. Chowdhury TA, Kumar S, Barnett AH, Bain SC. Nephropathy in type 1 diabetes: the role of genetic factors. Diabet Med 1995;12:1059-67. (Pubitemid 26009948)
13. Parving HH, Jacobsen P, Tarnow L et al. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study. BMJ 1996;313:591-4. (Pubitemid 26293643)
14. Cowie CC, Port FK, Wolfe RA et al. Disparities in incidence of end-stage renal disease according to race and type of diabetes. N Engl J Med 1989;321:1074-9. (Pubitemid 19256660)
15. Sawicki PT, Didjurgeit U, Muhlhauser I, Bender R, Heinemann L, Berger M. Smoking is associated with progression of diabetic nephropathy. Diabetes Care 1994;17:126-31. (Pubitemid 24035307)
16. Keane WF. Lipids and the kidney. Kidney Int 1994;46: 910-20. (Pubitemid 24272052)
17. Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003;289: 3273-7. (Pubitemid 37430080)
18. Tsalamandris C, Allen TJ, Gilbert RE et al. Progressive decline in renal function in diabetic patients with and without albuminuria. Diabetes 1994;43:649-55. (Pubitemid 24138777)
19. National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 update. Am J Kidney Dis 2012;60:850-86.
20. National Kidney Foundation. KDOQI Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Guideline 1: Screening and diagnosis of diabetic kidney disease. Am J Kidney Dis 2007;49(Suppl 2):S42-61.
21. Handelsman Y, Mechanick JI, Blonde L et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract 2011;17(Suppl 2): 1-53.
22. Atkins RC, Zimmet P; 2010 International Society of Nephrology/ International Federation of Kidney Foundations World Kidney Day Steering Committee (RA); International Diabetes Federation (PZ). Diabetic kidney disease: act now or pay later. J Bras Nefrol 2010;32:7-10.
23. Robertson L, Waugh N, Robertson A. Protein restriction for diabetic renal disease. Cochrane Database Syst Rev 2007;(4):CD002181.
24. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-Term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329: 977-86.
25. UK Prospective Diabetes Study Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352: 837-53.
26. Arauz-Pacheco C, Parrott MA, Raskin P; American Diabetes Association. Hypertension management in adults with diabetes. Diabetes Care 2004;27(Suppl 1):S65-7.
27. Haffner SM; American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care 2004;27(Suppl 1):S68-71.
28. Moorhead JF. Lipids and progressive kidney disease. Kidney Int Suppl 1991;31:S35-40.
29. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317: 703-13.
30. Remuzzi G, Macia M, Ruggenenti P. Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study. J Am Soc Nephrol 2006; 17(Suppl.2):S90-7
31. ROADMAP Trial Investigators; Haller H, Ito S, Izzo JL Jr et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011;364: 907-17.
32. Mathiesen ER, Hommel E, Giese J, Parving HH. Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ 1991;303:81-7.
33. Ahmad J, Siddiqui MA, Ahmad H. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 1997;20:1576-81. (Pubitemid 27415037)
34. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62. (Pubitemid 23335891)
35. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-Term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993;118:577-81. (Pubitemid 23102690)
36. Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus: A randomized, controlled trial. Ann Intern Med 1998;128:982-8. (Pubitemid 28275174)
37. The EUCLID Study Group. Randomized placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997;349:1787-92.
38. Viberti G, Mogensen CE, Groop LC, Pauls JF. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 1994;271:275-9. (Pubitemid 24030753)
39. Sano T, Kawamura T, Matsumae H et al. Effects of longterm enalapril treatment on persistent microalbuminuria in well-controlled hypertensive and normotensive NIDDM patients. Diabetes Care 1994;17:420-4. (Pubitemid 24145216)
40. Lebovitz HE, Wiegmann TB, Cnaan A et al. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int Suppl 1994;45: S150-5.
41. Nielsen FS, Rossing P, Gall MA, Skott P, Smidt UM, Parving HH. Long-Term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 1997;46:1182-8. (Pubitemid 27271080)
42. Fogari R, Zoppi A, Corradi L et al. Long-Term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function. J Hum Hypertens 1999;13:47-53. (Pubitemid 29042145)
43. Vivian EM, Goebig ML. Slowing the progression of renal disease in diabetic patients. Ann Pharmacother 2001;35: 452-63. (Pubitemid 32260213)
44. Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000;57:601-6. (Pubitemid 30430652)
45. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
46. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
47. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.
48. Barnett AH, Bain SC, Bouter P et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004;351:1952-61. (Pubitemid 39447136)
49. Viberti G, Wheeldon NM; MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002;106:672-8. (Pubitemid 34851925)
50. Lacourciere Y, Belanger A, Godin C et al. Long-Term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int 2000;58:762-9. (Pubitemid 30620026)
51. Mann JF, Schmieder RE, Dyal L et al. Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med 2009;151:1-10.
52. Wood JM, Maibaum J, Rahuel J et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003;308:698-705. (Pubitemid 36976519)
53. Katzung BG. Basic and Clinical Pharmacology. 11th ed. San Francisco, CA: McGrawHill; 2009.
54. Persson F, Rossing P, Reinhard H et al. Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care 2009;32:1873-9.
55. Persson F, Rossing P, Schjoedt KJ et al. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int 2008;73:1419-25. (Pubitemid 351770494)
56. Tutuncu NB, Gurlek A, Gedik O. Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: a prospective study. Acta Diabetol 2001;38:157-61. (Pubitemid 34145694)
57. Hebert LA, Falkenhain ME, Nahman NS, Cosio FG, O'Dorisio TM. Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy. Am J Nephrol 1999;19:1-6. (Pubitemid 29139863)
58. Agarwal R. Add-on angiotensin receptor blockade with maximized ACE inhibition. Kidney Int 2001;59:2282-9. (Pubitemid 32467622)
59. Rossing K, Christensen PK, Jensen BR, Parving HH. Dual blockade of the renin-Angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care 2002;25:95-100. (Pubitemid 41070790)
60. Jacobsen P, Andersen S, Rossing K, Jensen BJ, Parving HH. Dual blockade of the renin-Angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 2003;63:1874-80. (Pubitemid 36513336)
61. Rossing K, Jacobsen P, Pietraszek L, Parving HH. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care 2003;26:2268-74. (Pubitemid 36993311)
62. Fujisawa T, Ikegami H, Ono M et al. Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy. Am J Hypertens 2005;18:13-7. (Pubitemid 40187343)
63. Cetinkaya R, Odabas AR, Selcuk Y. Anti-roteinuric effects of combination therapy with enalapril and losartan in patients with nephropathy due to type 2 diabetes. Int J Clin Pract 2004;58:432-5. (Pubitemid 38786561)
64. Mogensen CE, Neldam S, Tikkanen I et al. Randomised controlled trial of dual blockade of renin-Angiotensin system in patients with hypertension, microalbuminuria, and noninsulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321:1440-4.
65. Mann JF, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547-53.
66. Mann JF, Anderson C, Gao P et al. Dual Inhibition of the renin-Angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial. J Hypertens 2013;31:414-21
67. Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Parving HH. Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy. Clin J Am Soc Nephrol 2011;6:1025-31.
68. ALTITUDE Investigators: Parving HH, Brenner BM, Mc-Murray JJ et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367:2204-13.
69. Harel Z, Gilbert C, Wald R et al. The effect of combination treatment with aliskiren and blockers of the renin-Angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-Analysis BMJ 2012;344:e42.